Aurora Therapeutics, cofounded by Nobel Prize–winning scientist Jennifer Doudna, plans to use gene editing and a new FDA regulatory pathway to commercialize treatments for rare diseases. Last February ...

Jennifer Garner is reflecting on her early career. The “13 Going on 30” star has revealed that she was always hesitant to discuss her breakthrough role in the ABC hit “Alias” because she was worried ...

Add Yahoo as a preferred source to see more of our stories on Google. A two-photo collage of Jennifer Garner. Jennifer Garner is reflecting on her early career. The “13 Going on 30” star has revealed ...

Jennifer Lawrence recalls missing out on 'Once Upon a Time in Hollywood' role. Christopher Polk/PMC/Andrew Cooper/Columbia Pictures/Courtesy Everett Collection After Margot Robbie channeled Sharon ...

Menlo Ventures has made a $16 million bet that the “baby KJ” custom CRISPR therapy success story is repeatable. The funding has enabled CRISPR co-inventor Jennifer Doudna, Ph.D., and baby KJ scientist ...

Jennifer Aniston might have strong thoughts about why Friends could never be revived, but the actress having long-lasting relationships with her co-stars always puts a big smile on the faces of fans.

Jennifer Aniston’s personal trainer Dani Coleman reveals the actress’ secret to her famously fit shape is her commitment to fitting in a workout regardless of her schedule. “No matter how much time or ...

From the basketball court to "The Jennifer Hudson Show" stage. Milwaukee Bucks forward Kyle Kuzma was a guest on the Daytime Emmy Award-nominated talk show's Tuesday, Jan. 13 episode. He even grooved ...

A headshot shows Jennifer Doudna in front of a gold background. Jennifer Doudna, a cofounder of Aurora Therapeutics, speaks during an interview in 2017 after being awarded the Japan Prize. Credit: AP ...

At 3 months old, Victoria Gray wouldn’t stop crying. Blood tests brought devastating news: she had sickle cell disease, a genetic blood disorder that blocks blood flow and oxygen delivery to the body.

Aurora Therapeutics' first target is the rare inherited disease phenylketonuria, also known as PKU. Here at MIT Technology Review we’ve been writing about the gene-editing technology CRISPR since 2013 ...